EUVIMEDEUVIMED entdecken
Open Access

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer

Grace M Choong iD, Tanya L Hoskin iD, Judy C Boughey iD, James N Ingle iD, Matthew P Goetz iD

Journal of Clinical Oncology · 2025-06 · 43 (16) · 1875-1885

DOI: 10.1200/jco-24-02263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-06. Verfasst von Grace M Choong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%) is unclear. METHODS Using the National Cancer Database, we studied patients with high-risk stage I to III, ER-low BC (defined as immunohistochemistry 1%-10%) who received (neo)adjuvant chemotherapy and did or did not initiate ET. OS was analyzed with ET initiation as a time-dependent covariate using Cox proportional hazards regression. RESULTS Of 10,362 patients with stage I to III ER-low BC, 7,018 received chemotherapy and met inclusion criteria. ET omission was 42% at 12 months and more common in patients with tumors that were progesterone receptor–negative, human epidermal growth factor receptor 2–negative, higher-grade (grade 2/3) and higher Ki-67 (≥20%; all P < .001) and those who received neoadjuvant chemotherapy (NAC; P < .001). With a median follow-up of 3 years, 586 deaths were observed. In a multivariable analysis, ET omission was associated with a higher risk of death (hazard ratio [HR], 1.23 [95% CI, 1.04 to 1.46]; P = .02), with a greater impact in those with higher ER levels: ER 1%-5% (HR, 1.15 [95% CI, 0.91 to 1.45]; P = .24) versus ER 6%-10% (HR, 1.42 [95% CI, 1.00 to 2.02]; P = .048). Among patients treated with NAC (n = 4,377, 62%), ET omission was associated with worse OS in those with residual disease (RD; HR, 1.26 [95% CI, 1.00 to 1.57]; P = .046) but not in those who achieved a pathologic complete response (HR, 1.06 [95% CI, 0.62 to 1.80]; P = .84). CONCLUSION In ER-low, early-stage BC, ET omission is associated with significantly worse OS, especially in patients with RD after NAC and those with higher (6%-10%) ER levels. Until prospective data are available, patients with ER-low BC should be counseled regarding the potential benefit of ET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsReceptors, EstrogenAntineoplastic Agents, HormonalHumansFemaleMiddle AgedNeoplasm StagingAgedChemotherapy, AdjuvantAdultReceptors, ProgesteroneNeoadjuvant TherapyProportional Hazards ModelsErb-b2 Receptor Tyrosine Kinases

Substanzen

Receptors, EstrogenAntineoplastic Agents, HormonalReceptors, ProgesteroneErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Oncology, Mayo Clinic, Rochester, MN.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN.

ORCID-Profile: Grace M Choong, Tanya L Hoskin, Judy C Boughey, James N Ingle, Matthew P Goetz

Förderung

  • NCI NIH HHS

Zitieren

APA

Choong, G. M., Hoskin, T. L., Boughey, J. C., Ingle, J. N., & Goetz, M. P. (2025). Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer. Journal of Clinical Oncology, 43(16), 1875-1885. https://doi.org/10.1200/jco-24-02263

Vancouver

Choong GM, Hoskin TL, Boughey JC, Ingle JN, Goetz MP. Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer. Journal of Clinical Oncology. 2025;43(16):1875-1885. doi:10.1200/jco-24-02263

BibTeX
@article{Choong2025,
  author = {Choong, Grace M and Hoskin, Tanya L and Boughey, Judy C and Ingle, James N and Goetz, Matthew P},
  title = {Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {16},
  pages = {1875--1885},
  doi = {10.1200/jco-24-02263}
}
Kostenlos starten →